CJC-1295 (No DAC) / GHRP-2 Blend
Also known as: CJC-1295 & GHRP-2, CJC-1295 No DAC + GHRP-2 Blend, Mod GRF 1-29 & GHRP-2
This blend pairs CJC-1295 without DAC (Mod GRF 1-29), a GHRH analog, with GHRP-2, a growth hormone secretagogue, to synergistically stimulate pulsatile growth hormone release. Both are unapproved research peptides.
Last updated
Mechanism of Action
CJC-1295 without DAC is a modified GHRH(1-29) analog that binds the pituitary GHRH receptor to amplify the amplitude of natural growth-hormone pulses. GHRP-2 is a synthetic ghrelin-mimetic that activates the growth-hormone-secretagogue receptor (GHS-R1a), triggering GH release through a distinct pathway and partially suppressing somatostatin tone. Combining a GHRH analog with a GHRP produces a synergistic, greater-than-additive GH pulse because the two receptors act on complementary signaling cascades. The no-DAC form has a short half-life that preserves pulsatile, physiologic GH and downstream IGF-1 release.
- Half-life
- Short for both components: roughly 30 minutes for CJC-1295 no DAC and about 15-30 minutes for GHRP-2
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Synergistic stimulation of pulsatile growth hormone release
- Raises downstream IGF-1 in research models
- Studied for lean mass, recovery, and body-composition endpoints
- Short-acting profile preserves physiologic GH pulsatility
- Two complementary GH-release pathways in one preparation
- Investigated for sleep quality and tissue repair
Potential Side Effects
- Injection-site redness or irritation
- Water retention, tingling, or numbness
- Increased appetite and elevated cortisol or prolactin (GHRP-2)
- Headache, flushing, or transient lightheadedness
- Possible reactive hypoglycemia
Common Dosing
For research use only and not medical advice: research protocols commonly combine roughly 100 mcg CJC-1295 (no DAC) with 100-200 mcg GHRP-2 per subcutaneous administration, often dosed 1-3 times daily on an empty stomach. No validated human dosing exists.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active or history of malignancy (GH and IGF-1 elevation)
- Uncontrolled diabetes or significant insulin resistance
- Pregnancy or breastfeeding
CJC-1295 (No DAC) / GHRP-6 Blend
This blend combines CJC-1295 without DAC (Mod GRF 1-29), a GHRH analog, with GHRP-6, a ghrelin-mimetic secretagogue noted for strong appetite stimulation, to synergistically boost growth hormone release. Both are unapproved research peptides.
GHRP-2
A growth hormone releasing peptide that strongly stimulates GH secretion via the ghrelin receptor. More potent than GHRP-6 with somewhat less appetite stimulation.
CJC-1295
A long-acting growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to produce more growth hormone. Often paired with a ghrelin mimetic for synergistic GH release.
Ipamorelin
A selective ghrelin receptor agonist (growth hormone secretagogue) prized for stimulating GH release with minimal effect on cortisol or prolactin. Considered one of the gentler GH peptides.
- View
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
2006
- View
Determinants of GH-releasing hormone and GH-releasing peptide synergy in men
2009
- View
Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature
1995
- View
Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men
2005